Undecimal Bio is an Israeli biotech and RNA therapeutics company1,2, headquartered in Cambridge and Tel Aviv2.
It has raised $18M across 1 funding round1; the most recent was a seed round of $18M1, announced Oct 13, 20261.
Funding history
| Round | Announced | Amount | Lead investors |
|---|---|---|---|
| Seed | Oct 13, 2026 | $18M | 4BIO Capital, IQ Capital |
Investors
Which Israeli startups are similar to Undecimal Bio?
Sources
- 1CTech by Calcalist, Oct 13, 2026. “Undecimal Bio raises $18 million Seed to tackle a key obstacle in RNA medicines”
- 2Laboratory Talk, Oct 17, 2026. “Latest Lab Talk News in Brief: Awards, seed funding, acquisitions and more…”
How much funding has Undecimal Bio raised?
Undecimal Bio has raised $18M across 1 funding round.
What was Undecimal Bio’s latest funding round?
Undecimal Bio’s most recent round was a seed round of $18M, announced Oct 13, 2026.
Who has invested in Undecimal Bio?
Investors in Undecimal Bio include 4BIO Capital, IQ Capital, Verve Ventures, Harel Tech, Entree Capital and Kerna Ventures, among others.
Where is Undecimal Bio based?
Undecimal Bio is based in Cambridge and Tel Aviv.